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Introduction
Fungal rhinosinusitis (FRS) is a potentially dangerous 
condition, depending on the type developed and the oppor-
tunity for diagnosis. It is a highly controversial subject in 
today’s medical world for the different research directions 
it offers [1, 2, 3].
In an attempt to elucidate the etiopathogenesis of rhi-
nosinusitis (RS), several controversial hypotheses have been 
launched. A true “storm” among otorhinolaryngologists oc-
curred in 1999 when Ponikau and Kern (Mayo Clinic, USA) 
launched the hypothesis that chronic rhinosinusitis (CRS) 
without nasal polyps has predominantly (in 93% of cases) a 
fungal etiology [1]. Despite the fact that until recently, bac-
teria have been considered responsible for CRS pathogen-
esis, the role of fungi is now recognized in the occurrence 
of certain forms of CRS. Fungal spores, by their ubiquitous 
nature, are always inhaled and stored in the respiratory tract 
mucosa. Although in healthy individuals in general, fungi 
have a saprophytic behavior, in some patients, under certain 
conditions, especially related to host immunity, fungi can 
induce diseases. FRS may include a wide variety of fungal 
infections that may vary in intensity, sometimes being lethal 
[2, 26].
Despite the recognition of FRS as a serious entity for 
more than two centuries and due to all studies carried out in 
recent years, the condition remains a controversial disease 
with evasive pathophysiology, incomplete knowledge about 
epidemiology and medical mycology. Further research is 
needed to elucidate the exact etiological and pathogenic 
role of fungal species in CRS, to improve FRS diagnosis and 
treatment in order to determine a better prognosis [1].
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Abstract
Background: Fungal rhinosinusitis is a major clinical problem which should be considered in all patients and immunocompromised patients with chronic 
rhinosinusitis. It may be non-invasive or invasive with five main subtypes. Acute invasive fungal rhinosinusitis affects immunocompromised patients, 
usually with poorly controlled diabetes. Orbital and intracranial invasions are common, and mortality is high, except in cases of early detection and 
aggressive treatment. Chronic invasive fungal rhinosinusitis and chronic granulomatous fungal rhinosinusitis are characterized by a prolonged clinical 
course with slow progression of the disease, frequent invasion of the orbit and skull. Allergic fungal rhinosinusitis is a disease of young atopic individuals. 
There are usually involved all the sinuses with mucosa thinning and specific secretions. Fungus ball appears in one sinus, most frequently in the maxillary 
sinus, and affected individuals are not usually atopic. Anatomical and physiological interactions of the nose and paranasal sinuses form a dynamic system. 
Mucus is the first line of defense against inhaled irritants and pathogens. The hygiene of a normal airway is maintained by the mucociliary clearance. The 
immune system includes nasal epithelial surface properties, or non-specific innate immunity and specific acquired immunity. 
Conclusions: The detailed knowledge of anatomical, histological and immunological properties of the nasal and sinus mucosa is essential for understanding 
the pathophysiology of sinus diseases, treatment planning and surgical approach in order to obtain a favorable result.
Key words: fungal rhinosinusitis, mycological examination, nasal mucociliary epithelium, immunology.
In recent years, the incidence of FRS has considerably 
increased due to patient’s survival, contemporary diagnostic 
equipment and high frequency of conditions favoring fun-
gal infections (diabetes mellitus, long-term pharmacological 
treatment with antibiotics, corticosteroids and immunosup-
pressants, radiotherapy, chemotherapy, immunodeficiency 
disorders). Fungal rhinosinusitis is classified into two main 
categories based on histopathological findings: invasive and 
non-invasive [1, 2, 3].
Epidemiology. Among patients with CRS, from 6% to 
12% are found to have fungi in culture or at histopathologi-
cal examination [40]. According to another study, 5-15% of 
all cases of CRS are considered RS of fungal etiology [41]. 
The incidence of fungal infections among patients oper-
ated for inflammatory rhinosinusitis accounts for 4.3% [43]. 
Globally, the FRS prevalence is about 900 million cases or 
15% of the world’s population [42].
In prospective studies, on large cohorts of patients with 
CRS (349-450 patients), FRS was diagnosed in 19.3-25.8% 
of cases. Approximately 10.3% of patients had allergic FRS 
(AFRS), 15.2% of patients - chronic FRS and 0.3% patients 
– fungus ball. Probably, the prevalence figures of different 
forms of FRS are underestimated because some patients 
with fungal diseases did not have clinical characteristics. 
This raised suspicions of FRS and therefore did not collect 
and send specimens for fungal analysis. In this case, the 
prevalence of non-invasive FRS may be higher [4, 5].
Etiology. The most common pathogens in FRS are As-
pergillus (Fumigatus, Flavus and Niger), which represent 
45% of all positive cultures, and Mucormycosis, but many 
other fungal species (Alternaria, Curvularia, Bipolaris, Can-
dida etc.) are also reported. These fungal spores are omni-
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present in the environment and can cause invasive and non-
invasive conditions [2, 4, 5, 6, 26].
FRS pathophysiology remains unknown. In order to 
develop, fungal hyphae and spores must penetrate a parana-
sal sinus, and the conditions should contribute to the fungal 
growth. These conditions develop when some disorders dis-
rupt normal mucociliary clearance (MCC) and / or obstruct 
sinus ostium [7]. The epithelial events, including specific 
and non-specific immunity, require a broader description 
because they allow understanding the physio-pathological 
mechanisms of FRS and are potential therapeutic targets [8]. 
In this context, we briefly recall the fundamental elements 
of rhinosinusal histology, immunology and physiology.
Notions of rhinosinusal histology. The internal plan of 
nasal pyramids consists of the nasal mucosa and the follow-
ing types of epithelium:
1. Pseudostratified columnar epithelium (respiratory 
epithelium) composed of five major cell types: ciliary cells 
(columnar), non-ciliary cells (columnar), caliciform cells, 
basal cells (small polygonal stem cells – progenitor cells of 
other cell types); and small granular cells. This epithelium is 
found in the two posterior thirds of the nasal cavity.
2. Squamous and transitional epithelium (stratified epi-
thelium containing cuboidal cells with microvilli) is found 
in the first third of the nasal cavity.
3. Epithelium of paranasal sinuses is a simple ciliary co-
lumnar type, with some caliciform cells and glands.
4. Olfactory epithelium in the olfactory area is a pseu-
dostratified epithelium containing olfactory cells, basal 
cells and Bowman glands (small serous alveolar glands) [9, 
10, 11].
The main glandular components of the lamina propria 
consist of serum glands, seromucous glands or Bowman 
glands. Seromucous glands and caliciform cells secrete acid 
glycoproteins (sialomucins and sulfomucins), while serum 
cells secrete neutral glycoproteins (fucomucin), enzymes 
(lysozyme, lactoferrin) and immunoglobulins [12].
The epithelial cells protect the upper and lower airways 
directly through MCC. The apical part of the ciliated cells, 
which accounts for about 80% of all epithelial cells, is cov-
ered by cilia (over 200 cilia per cell) whose apexes are lo-
cated in the periciliary layer. The frequency of ciliary beats, 
a determining factor in the mucociliary transport rate, is 
between 10 and 20 Hz (800-1000 beats per minute) at nor-
mal body temperature, and the ciliary rhythm/beat consists 
of three phases: fast forward rhythm/beat (effective move-
ment), during which the cilia expand to the maximum and 
are perpendicular to the cell surface, the tip being in contact 
with the mucus; the rest phase, in which the cilia are parallel 
to the cell surface and a slow return rhythm/beat (recovery 
rhythm/beat) [9, 10, 12, 13, 14].
The caliciform cells or mucus secreting cells produce an 
acid mucin in the amount of 0.1-0.3 mg/kg /day or 20-40 ml 
of mucus. The sufficient production of viscous, elastic and 
adhesive mucus is important in maintaining normal MCC. 
To prevent infections, mucus is weakly acidic, with a physi-
ological pH value of 5.5-6.5 and has the capacity of a small 
chemical buffer [9, 10, 11, 12, 14].
An outpatient study of monitoring nasal pH for 24-hours 
showed neither a diurnal pH variation nor significant fluc-
tuations in daily activities (ingestion of food and fluids, rest, 
sleep). The mean pH varied within the range of 5.97-7.85, 
while in the anterior part of the lower meatus the pH was 
higher than in the posterior part (7.1 versus 6.6) [15]. Ac-
cording to another study, the mean pH value in the nasal 
cavity was 6.3, while in the anterior part of the nasal cavity - 
6.40 (from 5.17 to 8.13) and in the posterior part of the nasal 
cavity - 6.27 (from 5.20 to 8.00) [16]. In patients with CRS, 
the pH in the middle meatus is alkaline and is on average 
7.81 ± 0.83, statistically significantly higher, compared to 
practically healthy subjects (7.35 ± 0.82, p = 0.00011) [17].
Both edema with the inflammation of the nasal mucosa 
and obstruction of sinus ostia may occur in the case of acid 
or alkaline nasal pH, resulting in ciliostasis – a cause known 
to develop CRS [18].
Therefore, the detailed knowledge of the mucosal histol-
ogy of each nasal anatomical portion is essential to under-
stand the pathophysiological mechanisms of nasal disorders 
and to plan the medical treatment and appropriate surgical 
intervention in order to obtain a favorable outcome.
Aspects of rhinosinusal physiology. The normal func-
tioning of paranasal sinuses depends on three essential 
components that ensure a continuous secretion clearance: 
normal secretion, ciliary function integrity, and ostial pa-
tency [9, 10, 11, 13, 14].
There are two mechanisms that protect the respiratory 
system against several irritants, microorganisms and in-
haled allergens – the nonspecific system (filtering function 
of the nose, nasal mucus with MCC and inflammatory re-
action) and specific system (humoral and cellular immune 
responses) [11].
Assessment of MCC along with the use of rhino-scin-
tigraphy and other objective and subjective methods in 
patients with CRS, with or without nasal polyps, treated 
medically and/or surgically, allows understanding of ciliary 
function and its role in CRS pathogenesis [19]. The ciliary 
function plays an important role in sinus clearance and pre-
vention of chronic inflammation. Although knowledge of 
CRS has considerably increased, there are very limited data 
on predisposing factors for these conditions. The mucocili-
ary transport speed is considered to be an important index 
of MCC function of the upper respiratory tract, an impor-
tant mechanism for the protection of the respiratory ciliary 
epithelium [8].
The average speed of mucus flow and particle transport 
in healthy adults and in normal conditions is about 5-6 mm/
min, ranging from 3 to 25 mm/min [9, 10]. Different fac-
tors may affect the ciliary function of epithelial cells. The 
MCC is reduced with age, being affected in the congenital 
abnormalities of the ciliary structure constitution (Karta-
gener triad, primary ciliary dyskinesia). The nasal mucosa 
dryness significantly affects the ciliary activity. At 50% rela-
tive humidity of inspired air, the ciliary motion stops after 
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8-10 minutes and at 30% relative humidity of inspired air – 
it stops after 3-5 minutes. The ciliary activity is optimal at 
32-40°C. At 19-32°C temperature, the frequency of ciliary 
beat increases, at temperature above 40°C it decreases, and at 
temperature 7-12°C and above 45°C the ciliary activity ceas-
es. Other factors, such as locally applied drugs, inhaled gas-
es, exposure to large amounts of wood dust and chromium 
vapor, tobacco smoke, infections (viral, bacterial, fungal), 
chronic rhinosinusitis (allergic rhinitis, CRS, nasal polyps) 
can severely affect the ciliary function [9, 10, 12, 13, 14].
CRS causes significant changes in nasal mucosa, includ-
ing secondary ciliary dysmorphology. These secondary 
changes may be reversible, but the time required to return 
to normal morphology depends on the severity of disorders, 
the persistence of the infection and other predisposing fac-
tors. Secondary ciliary dyskinesia and cytopathic epithelial 
changes play an important role in CRS pathophysiology 
[20].
Therefore, the anatomical and physiological interactions 
of the nose and paranasal sinuses form a dynamic system. 
Mucus forms a protective barrier to the airway epithelium; 
it is the first line of defense against the irritants and inhaled 
pathogens. The normal airway hygiene is maintained by 
MCC, the efficiency of which depends on the structure, 
number, movement, strength and coordination of cilia, 
quantity, composition and rheological properties of the 
periciliary layer and mucus layer, temperature. The unique 
rheological properties of mucus (viscosity, elasticity and ad-
hesion) are significant determinants of these two protective 
mechanisms.
Rhinosinusal immunology. The nasal immune system 
includes:
1. Superficial properties (mechanical, epithelial, physical 
characteristics of the mucus layer, mucociliary transport).
2. Inborn or non-specific immunity (bactericidal ac-
tivity of mucus, proteins – lactoferrin, lysozyme, α2-
macroglobulin, C-reactive protein, complement system, 
cellular – polymorphic cells and activated phagocytes, in-
cluding neutrophils, monocytes and macrophages).
3. Acquired or specific immunity (immunoglobulins – 
IgA, IgM, IgE and superficial IgG, informed macrophages, 
submucosal macrophages, IgM, IgG, T and B lymphocytes, 
mucosa-associated lymphoid tissue and remotely located 
(adenoids, lymph nodes and spleen) 11, 21, 22].
The 4 subclasses of IgG represent 75% of immunoglobu-
lins found in the serum, with a concentration of about 10 
mg/ml in healthy individuals. The least abundant immuno-
globulin in serum is IgE, with a normal concentration of 
approximately 150 ng/ml [23].
The defense mechanisms of the innate immunity are 
MCC, antimicrobial secretions and cells of the innate im-
mune system. The innate immunity involves a set of resis-
tance mechanisms, such as phagocytosis, which is not spe-
cific to a particular pathogen, while adaptive immunity has 
a high degree of specificity, such as the remarkable “mem-
ory” property. In spite of these differences, the innate and 
adaptive immune responses are linked and interact with 
each other, and both are necessary for an effective immune 
protection [21, 22].
The immune system cells responsible for the reaction 
and release of soluble molecules are lymphocytes (B and T), 
phagocytic cells (dendritic cells, macrophages, neutrophils 
and eosinophils) and auxiliary cells (basophils and mast 
cells). The molecules released by these cells are antibod-
ies, cytokines (interleukins - IL-1, IL-6, IL-8, IL-10, IL-12, 
TNF-α and interferons), chemokines, complement and var-
ious inflammatory mediators. There is evidence that IL-13 
is a central mediator that independently promotes eosino-
philic inflammation [21, 22].
IgA is a primary mucosa induced immunoglobulin; it is 
produced in humans more than any other class of immuno-
globulins, and its major role lies in mucosal immunity. IgA 
can trigger cellular functions, such as degranulation and 
respiratory activation. Most people with IgA deficiency are 
not ill, IgA deficiency being associated with a large number 
of specific disorders: sinopulmonary, gastrointestinal, auto-
immune and allergic diseases [21, 24].
The nose has two types of acquired cellular reactions as 
the first line of defense: IgA production, which forms in-
soluble complexes in mucus, and informed activated super-
ficial immunological cells which are capable of phagocyto-
sis. IgA is found in considerable amounts in nasal secretions 
[21, 24].
IgE is an immunoglobulin that causes allergic reactions 
and is mainly produced by lymphoid structures (tonsils and 
adenoids) and submucosa. IgE mediates immediate hyper-
sensitivity reactions and has a hypersensitivity impact on 
MCC function [21, 24].
Thus, the nasal immune system includes superficial 
properties (mechanical, epithelial, physical characteristics 
of the mucus layer, mucociliary transport), innate or non-
specific immunity (bactericidal activity of mucus, proteins, 
complement system, cellular immunity) and acquired or 
specific immunity (immunoglobulins, macrophages, T and 
B lymphocytes, lymphoid tissue).
Several predisposing factors for FRS (poor nutrition, 
low immunity, diabetes, long-term anti-TB treatment or 
antibiotics [25]) have been described, there are several pos-
sible pathophysiological pathways involving fungi in CRS 
and they can also act simultaneously or independently in a 
particular patient:
• Systemic or local IgE mediated reaction to fungi,
• Fulminant invasive infections – acute IFRS,
• Chronic invasive infections – chronic IFRS, chronic 
granulomatous IFRS,
• Epithelial lesions of superficial mucosa caused by eosi-
nophilic proteases (major basic protein),
• Impairment of epithelial barrier with subsequent im-
munological reaction,
• Biofilms containing fungi [26, 27, 28, 29].
The mucin in patients with CRS contains heterogeneous 
eosinophilic clusters with high level of eosinophilic granules 
of major basic protein, a toxic cationic protein for extracel-
lular microorganisms but also for the respiratory mucosa, 
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predisposing patients with CRS to secondary bacterial in-
fections. Eosinophils can migrate into the respiratory mu-
cosa by IL-13 expression, induced by adhesion molecules in 
the microvasculature, with subsequent migration from ves-
sels to tissues. Another cytokine – IL-5, by inhibiting apop-
tosis, promotes the differentiation, activation and survival 
of eosinophils in tissues [26, 30].
Exposure of peripheral blood mononuclear cells to fun-
gal antigens in vitro contributes to increased IL-5 and IL-
13 production in 89% of patients with CRS. The increase in 
humoral response (serum IgG) correlates strongly with the 
increase in cellular response (IL-5 production). Less than 
30% of patients with CRS have specific IgE antibodies to 
fungi [26, 30, 31].
These findings have led to a hypothesis in which fungi 
on the sinus mucosa surface could activate the immune sys-
tem in sensitized patients and induce cytokine production, 
which promotes the migration of eosinophils through the 
epithelium to mucin. Eosinophils reach the mucin contain-
ing fungi and release cationic proteins to destroy fungi, thus 
they perpetuate and potentially aggravate the inflammation 
of the mucous membranes observed in CRS. Therefore, re-
ducing the fungi in nasal and sinus cavities by antifungal 
treatment could reduce the immune and inflammatory re-
sponses in these clinically beneficial organisms of patients 
with CRS [26, 30].
Clinical trials with antifungal therapy for CRS, includ-
ing CRS with nasal polyps, contributed to a symptomatic 
improvement, but did not demonstrate a substantial clini-
cal effect [26, 32]. Some studies have found that antifungal 
treatment is safe and effective, reducing fungal antigenic 
load in nasal and paranasal cavities and then lowering the 
eosinophilic response. However, in order to determine the 
role of intranasal antifungal drugs in CRS treatment, con-
trolled and blind studies are required [30, 32].
Thus, fungi are more frequently involved as an impor-
tant pathogen in CRS etiology - they may play a minor role 
in CRS as part of a more complex multi-factor interaction, 
and conversely may be the main factor in some forms of 
CRS, however, fungi are not a universal etiological factor. 
However, the incidence and prevalence of various forms of 
FRS have not been accurately documented in prospective 
studies. It is crucial to estimate the exact physio-pathologi-
cal mechanism in order to determine whether any changes 
in the treatment of CRS are needed and, if so, how to address 
them. In order to establish adequate and effective therapeu-
tic strategies, and to minimize side effects, it is necessary 
to elucidate the pathophysiological mechanisms by which 
fungi initiate or perpetuate the inflammation, the nature of 
fungal interactions with the mucosal surface (e.g. as part 
of a biofilm or as a non-specific invader of disrupted epi-
thelial barriers), optimal drug delivery methods [1, 4].The 
presence of fungi in the sinus mucosa does not explain the 
chronic inflammation in patients with CRS because they are 
only in the mucus and histologically do not invade the tis-
sues. Since IgE antibodies to fungi have been detected in 
less than 50% of patients, type I hypersensitivity reaction in 
fungi does not fully explain the pathological process. There-
fore, CRS could be caused by an immunological response to 
fungi in nasal and sinus cavities of patients with CRS, but 
not necessarily type I hypersensitivity reaction [32].
Fungal infections of paranasal sinuses can manifest as 
two distinct entities. The most severe (invasive) infections 
occur in patients with a compromised immunity (malig-
nancies, autoimmune diseases, malnutrition, HIV infection, 
diabetes mellitus or immunosuppressive therapy) and are 
relatively easy to recognize by symptomatology and fulmi-
nant progression. The mortality rate is quite high in IFRS, 
early diagnosis and appropriate treatments are vital [33].
Non-invasive infections are chronic and, unfortunately, 
are often confused and treated as bacterial CRS for long pe-
riods of time, until the disease is exactly diagnosed [1, 33].
Clinical picture.  FRS can often be difficult to diagnose, 
since its symptoms may be easily confused with the symp-
toms of bacterial CRS. The most common symptoms are 
pressure and /or numbness in the face area, frequent nasal 
congestion, inflammation of sinuses, nasal polyps, frequent 
sneezing, cough, headache, facial pain [6].
The clinical picture of invasive infections involves the 
presence of a viscous dark secretion in sinus cavities, spread-
ing into adjacent tissues – orbit and intracranial structures 
[6].
FRS classification.  To be able to predict patient’s prog-
nosis and response to treatment, a FRS classification is 
needed. It is important to make a distinction between inva-
sive and non-invasive forms of FRS. All attempts to system-
atize FRS confirm that there is no single opinion concerning 
FRS so far, but fungi are definitely involved in its etiopatho-
genesis, and its incidence and prevalence are much higher 
than previously thought [1, 26 ].
Currently, most rhinologists acknowledge the following 
clinical and pathological forms of FRS:
1. Non-invasive FRS (absence of mucosal layer invasion):
• Local colonization with saprophytic fungi
• Fungus ball
• FRS caused by eosinophils (AFRS, eosinophilic FRS, 
eosinophilic mucin RS).
2. IFRS (with mucous layer invasion):
• Acute (fulminant) IFRS,
• Chronic IFRS,
• Chronic granulomatous (indolent) IFRS [2, 33, 34, 35].
Therefore, there is invasive and non-invasive FRS. Acute 
FRS includes acute IFRS (fulminant), and chronic FRS - 
chronic IFRS, chronic granulomatous IFRS, fungus ball, 
AFRS. FRS forms are distinct entities with different clinical, 
laboratory and radiological characteristics. Each FRS form 
can be differentiated and has different treatment and prog-
nosis approaches.
General criteria for diagnosing different types of FRS. The 
most important step in FRS management is correct diag-
nosis, based on solid criteria, which will lead to a better 
prognosis of this condition. Due to potential invasiveness, 
especially in patients at risk, a correct and rapid diagnosis of 
FRS is essential in order to initiate the treatment as early as 
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possible and to ensure a favorable prognosis. FRS diagnosis 
should be based on clinical examination and paraclinical in-
vestigations, the most important of which is histopathologi-
cal evidence of fungi presence [1].
Two essential conditions are required for FRS diagno-
sis: RS diagnosis (the ubiquitous nature of fungi should not 
be forgotten) and evidence of fungal infection. The latter 
can be confirmed by histopathological and/or mycological 
examination. Histopathology, according to some literature 
data, is still the standard method ensuring the best sensitiv-
ity in the detection of rhinosinusal fungal infection. Myco-
logical examination is a useful tool and has a certain value, 
but it involves special conditions for harvesting, transport-
ing and processing in order to obtain positive results. Cor-
rect sample harvesting and transporting are essential for the 
precise identification of fungi [1].
The diagnosis of FRS begins with a detailed anamnesis. 
Often, patients have a history of rhinosinusitis for prolonged 
periods of time or rhinosinusitis refractory to medical or 
surgical treatment for bacterial CRS [1, 25].
Histopathological (anatomopathological) examination 
is a quick and relatively inexpensive technique that often 
confirms the positive diagnosis or, at least, induces a sus-
picion of diagnosis. It detects the presence of fungi and 
confirms the tissue invasion. In addition, some histopath-
ological parameters in CRS are predictive of the favorable 
response to functional endoscopic sinus surgery [1, 36, 
37]. The histopathological examination for the detection 
of fungi reveals inflammatory cells in tissues and mucus, as 
well as the existence of specific reactions (Charcot-Leyden 
crystals). Staining can be done using hematoxylin-eosin, 
periodic Schiff acid or Grocott-Gomori silver hexamine im-
pregnation, the latter can also identify fungal morphology 
[1]. However, some fungi (Aspergillus and Mucorales) have 
a similar morphology, making it difficult to distinguish be-
tween them by Grocott-Gomori silver hexamine stain. Im-
munohistochemical staining MUC5B is a much more sen-
sitive method for the detection and identification of fungi 
in FRS, especially differentiating Aspergillus species from 
Mucorales species [44].
Mycological examination is also an essential step in the 
analysis and can be done with or without staining. The poor 
sensitivity of fungal sinus culture techniques with signifi-
cant false-negative rates makes difficult the determination 
of the exact FRS incidence and prevalence [4]. The fungal 
detection rates using the culture method vary greatly – from 
6% to 93% [43, 45]. Since fungi cultures are frequently nega-
tive, Bent and Kuhn have accepted that if all the other diag-
nostic criteria exist, including the positive histopathological 
examination of the sinus mucin, positive fungal culture is 
not required to confirm the diagnosis [38].
The usefulness of immunofluorescence techniques in 
the diagnosis of fungal infections has been confirmed in 
many studies. They can be used to early detect and identify 
fungi on different cultures or almost any biological product 
(blood, urine, cerebrospinal fluid, etc.) [1].
To diagnose fungal infections, there are some other 
techniques using the immunoassay (ELISA) to determine 
active antigens or genomic amplification by molecular biol-
ogy techniques (polymerase chain reaction – PCR) [1].
The serological test aims at identifying specific immu-
noglobulins that are a marker of early or present fungal 
infection. It is noteworthy that two essential conditions 
are required to determine specific serum IgG: long enough 
contact of the fungal antigen with the host immune system 
and competent host immune system. This explains why the 
serological test is negative in localized fungal infection of 
fungus ball and in immunosuppressed patients (AIDS, leu-
kemia, etc.) [1].
Skin tests are very important diagnostic tools in the case 
of allergic fungal disease. Lately, skin prick tests have be-
come a norm, standardizing fungal extracts for classical in-
tradermal tests [1].
Unfortunately, we have no standard criteria for imag-
ing diagnosis of FRS. CT scan is the most useful imaging 
method, due to an increased sensitivity and ability to iden-
tify signs at early stages, but with reduced specificity for this 
condition. CT is performed at a 3 mm interval in the axial 
and coronal planes, using both bone and tissue windows. 
Magnetic Resonance Imaging (MRI) has a limited value for 
RSF diagnosis, being a starting point for the diagnosis of 
these clinical entities. It is often required in order to double 
the CT examination [1].
Several suspicions about FRS diagnosis are described:
• Isolated damage to a paranasal sinus (maxillary, sphe-
noid) or asymmetric disorders (significant percentage 
of unilateral damage) with opacification and calcifica-
tion inside and / or different density on CT scans, hy-
posignal in secretion and hypersignal in the mucosa 
injured on T2 sections of MRI.
• Exacerbated facial pain, signs and symptoms non-spe-
cific to RS (nasal congestion, headache, rhinorrhea, 
etc.), nasal and facial edema.
• Severe thick brownish (mucin) and / or caseous secre-
tion during endoscopic diagnosis or during surgery.
• Ischemic or necrotic areas on endoscopic or surgical 
examination.
• Direct examination of secretions with degranulated 
and / or necrotic eosinophils (Charcot-Leyden crys-
tals).
• Direct identification of hyphae, if positive culture is 
negative, if both are negative – positive PCR (con-
sidering the clinical and radiological data described 
above).
• Mucosa with non-specific inflammation, if the fungus 
is present in the epithelium, submucosa and / or bone 
- invasive presentation (correlates with the clinical 
characteristics, findings and patient`s immune status).
• Clinical and radiological presentation similar to eosi-
nophilic mucin; there are no available methods for 
positive fungal identification, which may indicate 
non-fungal eosinophilic CRS (mucinic, atopic or non-
atopic).
• The presence of fungi on direct examination by cul-
47
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ture harvesting and / or PCR can also be determined 
in normal subjects [35].
The diagnosis of FRS is primarily histological. The dis-
tinction between IFRS and non-invasive FRS is based on 
histopathological evidence of fungal invasion of the sinus 
and bone mucosa and, eventually, spread to the adjacent 
structures and tissues (orbit, anterior skull base and ptery-
gopalatine fossa). In non-invasive FRS, fungal infection is 
limited to the sinus cavity without fungal invasion of the 
mucous membrane and bones [6].
Non-invasive FRS includes fungus ball and AFRS, which 
generally do not invade bone or tissues and, more common-
ly, are a result of skin hypersensitivity reactions. But a long-
term development of the disorder may eventually erode the 
bone (osteitis, osteomyelitis) that may cause an intracranial 
or intraorbital complication. Complications may occur in 
an immunocompetent patient and are characterized by the 
presence of allergic mucin, Charcot-Leyden crystals, eosin-
ophils and other inflammatory cells [6, 25, 34].
The diagnosis of fungus ball is often delayed because the 
symptoms are generally similar to those of bacterial CRS, 
the course of the disease is slow, oligosymptomatic and non-
invasive. At the same time, fungus ball tends to appear in 
a single sinus, unilaterally, most often in the maxillary si-
nus, usually the affected individuals being non-atopic. The 
sinus contains hyper attenuated material and there may be 
evidence of chronic sinus disease or smooth bone erosion. 
Surgical removal is the basic treatment, recurrences being 
unusual [34].
AFRS is more common in young atopic people. Pansi-
nusitis is usually found with expansion and thinning of the 
affected sinuses. The disease is characterized by the presence 
of allergic mucin, Charcot-Leyden crystals and eosinophils 
[6, 25, 34, 46]. The sinus content is hyper attenuated with 
high signal intensity on MRI images T1 and low signal in-
tensity on MRI images T2. Surgical extirpation and antial-
lergic remedies are the basis of the treatment, the systemic 
or local antifungal toxic therapy not being necessary [34].
IFRS is a more fatal condition, defined by the presence 
of fungal hyphae in the mucosa, submucosa, bones or blood 
vessels of paranasal sinuses with orbital and intracranial ex-
tension. These subtypes are distinct entities with different 
clinical and radiological characteristics, with different treat-
ment and prognosis strategies, which predominantly occur 
in immunocompromised patients in about 50% of cases. 
According to some studies, IFRS incidence is 0.5-4% of pa-
tients with bone marrow transplant. The imaging features 
are often subtle at the initial stages, and sinus evaluation 
in these patients is performed to determine early invasion 
signs. The mortality rate tends to be high, except the cases 
of early detection and aggressive treatment. In patients with 
untreated IFRS the mortality is significant and may reach 
85-100% [3, 25, 34, 35, 39].
The risk factors for RSFI development include the use 
of antibiotics for prolonged periods of time, permanent si-
nonasal catheter, prolonged nasal intubation, immunosup-
pressive medications, metabolic or steroid abnormalities, 
poorly controlled diabetes, long neutropenia, and sinus dis-
ease [3].
The acute forms of IFRS progress rapidly within hours or 
days to fulminant intracranial infections. The chronic forms 
show slow growth and cause slow tissue destruction with 
subsequent invasion. Disease duration of less than 4 weeks 
differentiates acute form from chronic one. The term ”sub-
acute IFRS” can be used in rare situations – in patients with 
disease duration within 1-3 months [25, 34, 39, 42].
Chronic IFRS and chronic granulomatous IFRS are 
characterized by a long-lasting clinical development (more 
than 3 months) with slow progression of the disease, orbital 
complications and intracranial complications. Imaging ma-
nifestations can mimic agressive neoplastic lesions [34, 42].
FRS complications range from relatively benign to po-
tentially lethal and are divided into three categories:
• Local - mucocele of paranasal sinuses, frontal bone os-
teomyelitis, subperiosteal abscess of the frontal bone,
• Orbital - inflammatory edema, orbital (post septal) cel-
lulitis, subperiosteal abscess, orbital abscess, cavern-
ous sinus thrombosis,
• Intracranial - meningitis, epidural abscess, subdural 
abscess, intracerebral abscess, cavernous sinus throm-
bosis, upper sagittal sinus thrombosis [25].
The intracranial, insidious and rapid extension is the 
most feared complication of IFRS with high mortality rates. 
The following forms of extension are known: 1) direct – the 
most common, 2) haematogenic – dangerous and asymp-
tomatic with emboli and mycotic thrombus formation, 3) 
perineural with the cranial nerves paralysis and extension to 
the base of the anterior skull, 4) through the cribriform plate 
of the ethmoid bone at the base of the anterior skull, 5) very 
rarely by surgery or blood transfusion [25].
Therefore, the most appropriate approach is early di-
agnosis and intervention. With the current available diag-
nostic means (CT, MRI, microscopic examination, cultures 
and nasal endoscopy), diagnosis is much simpler, however, 
a high degree of clinical suspicion is required. The treatment 
results have greatly improved with advances in medical and 
surgical technology. New antifungal agents and other rem-
edies have greatly contributed to better results through in-
creased efficacy and minimized toxic side effects of tradi-
tional medicines [25].
FRS management is divided into two main directions: 
surgical treatment - which is aimed at eliminating fungal 
antigen and is most commonly the main treatment and con-
servative treatment – which seeks to prevent relapses, but 
has not been standardized so far and there is no clear evi-
dence of the efficacy of any of the therapeutic agents used. 
Functional endoscopic sinus surgery is used together with 
long-term conservative treatment, oral and intranasal glu-
cocorticosteroids, immunotherapy, antifungal medication 
and antimicrobial agents [25].
Functional endoscopic sinus surgery is the main option. 
There are various surgical methods in FRS. In the case of 
non-invasive and invasive disease, which is limited to si-
nuses without obvious dural involvement or osteomyelitis, 
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endoscopic elimination is the method of choice. If there 
is FRS extension, particularly intracranial extension, non-
endoscopic approaches with the involvement of neurosur-
geons team are considered [25].
In fungus ball, surgery always resolves the disease with-
out the need for further pharmacological treatment. In 
AFRS, surgical treatment improves the symptoms of nasal 
respiratory obstruction, but local drug therapy is neces-
sary. With the help of medical treatment, surgery resolves 
chronic IFRS and prevents the intracranial spread of com-
plications. In patients with acute (fulminant) IFRS, timely 
surgical treatment prevents the onset of intracranial compli-
cations and makes the antimycotic polychemotherapeutic 
treatment possible in order to control the disease [43, 47].
The main pillar of the medical treatment of FRS is the 
administration of antifungal preparations: Amphotericin B 
at a maximum dose of 2-4 g/day, Lipozomal Ampho B at a 
dose of 4 mg / kg / day and can be increased to 10-15 mg / 
kg / day, fluconazole or itraconazole 400 mg twice daily [25].
Postoperative treatment includes regular endoscopic ex-
amination and follow-up, nasal lavage twice daily with Am-
photericin B. Antifungal preparations are continued for ap-
proximately 4 weeks or until complete recovery confirmed 
by endoscopic examination [25].
Conclusions
FRS is one of the most challenging diseases for otorhi-
nolaryngologists, primarily in terms of diagnosis and treat-
ment. Because of the lack of standard diagnostic criteria and 
the potential FRS invasiveness, especially in at-risk patients, 
it is essential to have a correct and rapid diagnosis in order 
to initiate treatment as quickly as possible to get a favorable 
prognosis. The only way to establish a reliable diagnosis is 
to perform a detailed clinical examination and biopsy sam-
pling [1].
FRS is an important clinical issue with various manifes-
tations that should be considered in all immunocompro-
mised patients and in all patients with CRS. It may be inva-
sive or non-invasive, with five main subtypes [34].
Acute IFRS affects immunocompromised patients and 
patients with poorly controlled diabetes. The orbital and in-
tracranial invasion is common, and mortality is high, except 
in cases of early detection and aggressive treatment. The im-
aging features are subtle at the initial stages and require at-
tention to detect early signs of invasion [34].
Chronic IFRS and chronic granulomatous IFRS are 
characterized by a prolonged clinical development, slow 
progression of the disease, orbital and cranial invasion. Im-
aging manifestations can mimic aggressive neoplastic le-
sions [34].
AFRS is a disease of young atopic individuals. There is 
usually pansinusitis expansion and thinning of the affected 
sinuses. The contents of sinuses are hyper attenuated, with 
an increased signal intensity of T1 and a low signal inten-
sity of T2 on MRI images. Surgical removal and antiallergic 
treatment are the main management methods, systemic or 
local antifungal toxic treatment not being necessary [34].
Fungus ball occurs in a single, unilateral sinus, most 
commonly in the maxillary sinus, and the affected individu-
als are usually not atopic. Sinuses contain hyper attenuated 
material and there may be evidence of chronic rhinosinus-
itis or smooth bone erosion. Surgical removal is the method 
of choice, the recurrence being unusual [34].
Therefore, understanding the different types of FRS and 
their special radiological characteristics allows diagnosing 
and initiation of the early treatment to avoid a delayed out-
come, complications or fatal outcomes.
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